85 related articles for article (PubMed ID: 31121497)
21. Cytokines in the Treatment of Cancer.
Conlon KC; Miljkovic MD; Waldmann TA
J Interferon Cytokine Res; 2019 Jan; 39(1):6-21. PubMed ID: 29889594
[TBL] [Abstract][Full Text] [Related]
22. The localisation of the heparin binding sites of human and murine interleukin-12 within the carboxyterminal domain of the P40 subunit.
Garnier P; Mummery R; Forster MJ; Mulloy B; Gibbs RV; Rider CC
Cytokine; 2018 Oct; 110():159-168. PubMed ID: 29753267
[TBL] [Abstract][Full Text] [Related]
23. Improvements to the APBS biomolecular solvation software suite.
Jurrus E; Engel D; Star K; Monson K; Brandi J; Felberg LE; Brookes DH; Wilson L; Chen J; Liles K; Chun M; Li P; Gohara DW; Dolinsky T; Konecny R; Koes DR; Nielsen JE; Head-Gordon T; Geng W; Krasny R; Wei GW; Holst MJ; McCammon JA; Baker NA
Protein Sci; 2018 Jan; 27(1):112-128. PubMed ID: 28836357
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Interleukin-12 activity in the presence of heparin.
Jayanthi S; Koppolu BP; Nguyen KG; Smith SG; Felber BK; Kumar TKS; Zaharoff DA
Sci Rep; 2017 Jul; 7(1):5360. PubMed ID: 28706183
[TBL] [Abstract][Full Text] [Related]
25. Solution NMR characterization of chemokine CXCL8/IL-8 monomer and dimer binding to glycosaminoglycans: structural plasticity mediates differential binding interactions.
Joseph PR; Mosier PD; Desai UR; Rajarathnam K
Biochem J; 2015 Nov; 472(1):121-33. PubMed ID: 26371375
[TBL] [Abstract][Full Text] [Related]
26. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.
Floros T; Tarhini AA
Semin Oncol; 2015 Aug; 42(4):539-48. PubMed ID: 26320059
[TBL] [Abstract][Full Text] [Related]
27. Efficient production and purification of recombinant human interleukin-12 (IL-12) overexpressed in mammalian cells without affinity tag.
Jayanthi S; Koppolu Bp; Smith SG; Jalah R; Bear J; Rosati M; Pavlakis GN; Felber BK; Zaharoff DA; Kumar TK
Protein Expr Purif; 2014 Oct; 102():76-84. PubMed ID: 25123642
[TBL] [Abstract][Full Text] [Related]
28. IFN-γ primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b.
Wu C; Xue Y; Wang P; Lin L; Liu Q; Li N; Xu J; Cao X
J Immunol; 2014 Sep; 193(6):3036-44. PubMed ID: 25092892
[TBL] [Abstract][Full Text] [Related]
29. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.
Mittal D; Gubin MM; Schreiber RD; Smyth MJ
Curr Opin Immunol; 2014 Apr; 27():16-25. PubMed ID: 24531241
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation.
Zhou F
Int Rev Immunol; 2009; 28(3-4):239-60. PubMed ID: 19811323
[TBL] [Abstract][Full Text] [Related]
31. The structure of glycosaminoglycans and their interactions with proteins.
Gandhi NS; Mancera RL
Chem Biol Drug Des; 2008 Dec; 72(6):455-82. PubMed ID: 19090915
[TBL] [Abstract][Full Text] [Related]
32. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12.
Lupardus PJ; Garcia KC
J Mol Biol; 2008 Oct; 382(4):931-41. PubMed ID: 18680750
[TBL] [Abstract][Full Text] [Related]
33. Biological implications of glycosaminoglycan interactions with haemopoietic cytokines.
Coombe DR
Immunol Cell Biol; 2008 Oct; 86(7):598-607. PubMed ID: 18626488
[TBL] [Abstract][Full Text] [Related]
34. Measurement of human and mouse interleukin-12.
Gately MK; Chizzonite R; Presky DH
Curr Protoc Immunol; 2001 May; Chapter 6():6.16.1-6.16.15. PubMed ID: 18432807
[TBL] [Abstract][Full Text] [Related]
35. Antibody-cytokine fusion proteins: applications in cancer therapy.
Ortiz-Sánchez E; Helguera G; Daniels TR; Penichet ML
Expert Opin Biol Ther; 2008 May; 8(5):609-32. PubMed ID: 18407765
[TBL] [Abstract][Full Text] [Related]
36. Cytokines and proteoglycans: an introductory overview.
Mulloy B; Rider CC
Biochem Soc Trans; 2006 Jun; 34(Pt 3):409-13. PubMed ID: 16709174
[TBL] [Abstract][Full Text] [Related]
37. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
Helguera G; Rodríguez JA; Penichet ML
Mol Cancer Ther; 2006 Apr; 5(4):1029-40. PubMed ID: 16648575
[TBL] [Abstract][Full Text] [Related]
38. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
[TBL] [Abstract][Full Text] [Related]
39. Antibody-cytokine fusion proteins for the therapy of cancer.
Helguera G; Penichet ML
Methods Mol Med; 2005; 109():347-74. PubMed ID: 15585931
[TBL] [Abstract][Full Text] [Related]
40. A method for the non-covalent immobilization of heparin to surfaces.
Mahoney DJ; Whittle JD; Milner CM; Clark SJ; Mulloy B; Buttle DJ; Jones GC; Day AJ; Short RD
Anal Biochem; 2004 Jul; 330(1):123-9. PubMed ID: 15183770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
